Table 1.
Descriptive characteristics of HAART-treated VHIV children with virological suppression
| Characteristic | n (%) | Median (IQR) | Global range |
|---|---|---|---|
| Age (years) | — | 9 .8 (7–13 .1) | 2 .8–19 |
| Sex | |||
| female | 38 (39) | — | — |
| male | 59 (61) | — | — |
| cART maternal prophylaxis type | |||
| 2 NRTIs + 1 NNRTI | 60 (62) | — | — |
| 2 NRTIs + 1 PI | 37 (38) | — | — |
| Age at HAART initiation (years) | — | 3 .3 (1 .9–7) | 0 .41–16 |
| Duration of HAART (years) | — | 5 .4 (3 .5–7) | 0 .33–12 .1 |
| WHO stage at HAART initiation | |||
| 1 or 2 | 36 (39) | — | — |
| 3 or 4 | 52 (61) | — | — |
| missing data: 9 | |||
| HAART type at study | |||
| 2 NRTIs + 1 NNRTI | 61 (63) | — | — |
| 2 NRTIs + 1 PI | 36 (37) | — | — |
| CD4 cell count at study (cells/mm3) | — | 820 (605–1120) | 46 –2000 |
| missing data: 1 | |||
| HIV DNA level at study (copies/106 cells) | — | 445 (87–902) | 0 –7378 |
| <66 copies/106 cells (i .e . undetectable) | 12 (13) | — | — |
| missing data: 2 | |||
| Anti-gp41 antibodies activity at study (OD) | — | 0 .29 (0 .18–0 .75) | 0 .09–2 .23 |
| missing data: 9 | |||
| Anti-HIV antibodies level at study (S/CO) | — | 14 .1 (4 .1–39 .3) | 0 .31–520 .6 |
| <1 .0 S/CO (i .e . seroconversion) | 8 (9) | — | — |
| missing data: 10 | |||
cART, combination ART .